Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2026 22:48 ET | Source: Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio (IBRX) Investors Have Opportunity to Lead ImmunityBio, Inc Securities Fraud Lawsuit
April 28, 2026 21:18 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atara (ATRA) To Contact Him Directly To Discuss Their Options If you purchased or...
April 28, 2026 19:31 ET | Source: Hagens Berman Sobol Shapiro LLP

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 28, 2026 10:59 ET | Source: The Rosen Law Firm PA

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026...
April 28, 2026 09:50 ET | Source: Schall Law

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026 07:47 ET | Source: Bernstein Liebhard LLP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

ImmunityBio Shareholders Between January 19, 2026 and March 24, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
April 27, 2026 09:00 ET | Source: Portnoy Law

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors...
April 25, 2026 09:11 ET | Source: The Rosen Law Firm PA

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026...
April 24, 2026 22:12 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 24, 2026 15:30 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX Lawsuit Alleges Misleading Cancer Claims - ImmunityBio Investors Face Losses Following $2B Market Cap Loss – Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.